関連する実験動画
Updated: Jan 13, 2026

07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
34.7K
てんかん関連の分子変化におけるFKBP5発現の上昇と神経興奮性の亢進
Meng Cai1, Shuyang Wang1, Mingsu Liu1
1Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Brain research
|January 10, 2026
まとめ
FKBP5タンパク質レベルはてんかんモデルで増加し、神経興奮性とグルタミン酸レベルを亢進させます。確認にはさらなる研究が必要です。
科学分野:
- 神経科学
- 分子生物学
背景:
- てんかんは、神経興奮性の亢進による再発性の発作を特徴とする神経疾患です。
- FKBP5は、アルツハイマー病やパーキンソン病などの他の神経疾患にも関与しています。
研究 の 目的:
- カイニン酸(KA)誘発てんかんモデルにおけるFKBP5の役割を調査する。
- 神経伝達物質の動態と神経興奮性に対するFKBP5の機能獲得およびFKBP51阻害の効果を評価する。
主な方法:
- KA誘発てんかんマウスモデルの海馬におけるFKBP5の発現を調べた。
- 細胞外グルタミン酸を評価するために、初代ニューロンおよびアストロサイトでFKBP5を過剰発現させた。
- 神経興奮性とネットワーク活動を評価するために、ホールセルパッチクランプおよびHD-MEAを利用した。
主要な成果:
- KA誘発てんかんモデルマウスの海馬におけるFKBP5の高発現。
- FKBP5の過剰発現は、Na+電流の増強を含む細胞外グルタミン酸と神経興奮性を増加させました。
- FKBP5の過剰発現によりネットワーク活動は興奮性の亢進を示しました。SAFit2処理もグルタミン酸を増加させました。
結論:
- FKBP5は神経興奮性とグルタミン酸ホメオスタシスに大きく影響します。
- invivoデータはてんかん発生におけるFKBP5の役割を示唆していますが、因果関係についてはさらなる調査が必要です。
- 将来の研究では、確定的な結論を得るためにEEGモニタリングと細胞種特異的な操作を統合する必要があります。
関連する概念動画
Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
804
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804
Antiepileptic Drugs: Potassium Channel Activators
620
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
620
Antiepileptic Drugs: Glutamate Antagonists
880
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
880
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K

